Dissecting the dynamics of serum prostate-specific antigen

American Journal of Clinical Pathology

Volumn 133, Issue 2, 2010, Pages 187-193

  Vollmer, Robin T ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Dynamics; Kinetics; Prostate cancer; PSA; PSA velocity; Serum prostate specific antigen; Tumor histology; Tumor volume

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; REFERENCE VALUE; STATISTICAL MODEL; TUMOR VOLUME; BIOLOGICAL MODEL; BLOOD; KINETICS; MIDDLE AGED; PATHOLOGY; PROSTATE; PROSTATE TUMOR; TIME;

AGED; HUMANS; KINETICS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 77449142899     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/AJCP3CJR3IDRCFEO     Document Type: Article

References (51)

1. Stamey TA, Yang N, Hay AR, et al. Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317:909-916 (Pubitemid 17147932)
2. Stamey TA, Kabalin JN. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate, I: untreated patients. J Urol. 1989;141:1070-1075 (Pubitemid 19124200)
3. Carter HM, Morrell CH, Pearson JD, et al. Estimation of prostatic growth using serial prostate specific antigen measurements in men with and without prostate cancer. Cancer Res. 1992;52:3323-3328
4. Brawer MK, Beatie J, Wener MH, et al. Screening for prostatic carcinoma with prostate specific antigen: results of the second year. J Urol. 1993;150:106-109 (Pubitemid 23175982)
5. Schmid H-P, McNeal JE, Stamey TA. Observations on the doubling time of prostate cancer: the use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer. 1993;71:2031-2040
6. Zagars GK, Pollack A. The fall and rise of prostate-specific antigen: kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancer. Cancer. 1993;72:832-842 (Pubitemid 23215273)
7. Cox RS, Kaplan ID, Bagshaw MA. Prostate-specific antigen kinetics after external beam irradiation for carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1994;28:23-31 (Pubitemid 24012851)
8. Pollack A, Zagars GK, Kavadi VS. Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer. Cancer. 1994;74:670-678 (Pubitemid 24217632)
9. D'Amico AV, Hanks GE. Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer. Cancer. 1993;72:2638-2643
10. Partin AW, Pearson JD, Landis PK, et al. Evaluation of serum prostate specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology. 1994;43:649-659
11. Pearson JD, Carter HB. Natural history of changes in prostate specific antigen in early stage prostate cancer. J Urol. 1994;152:1743-1748 (Pubitemid 2432261 9)
12. Littrup PJ, Kane RA, Mettlin CJ, et al. Cost-effective prostate cancer detection: reduction of low-yield biopsies. Cancer. 1994;74:3146-3158
13. Mettlin C, Littrup PJ, Kane RA, et al. Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age-referenced PSA, PSA density, and PSA change. Cancer. 1994;74:1615-1620
14. Kadmon D, Weinberg AD, Williams RH, et al. Pitfalls in interpreting prostate specific antigen velocity. J Urol. 1996;155:1655-1657 (Pubitemid 26126970)
15. Keetch DW, McMurtry JM, Smith DS, et al. Prostate specific antigen density versus prostate specific antigen slope as predictors of prostate cancer in men with initially negative prostate biopsies. J Urol. 1996;156:428-431 (Pubitemid 126445356)
16. Thiel R, Pearson JD, Epstein JI, et al. Role of prostate-specific antigen velocity in prediction of final pathologic stage in men with localized prostate cancer. Urology. 1997;49:716-720 (Pubitemid 27194586)
17. Patel A, Dorey F, Franklin J, et al. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol. 1997;158:1441-1445 (Pubitemid 27391215)
18. Pruthi RS, Johnstone I, Tu I-P, et al. Prostate specific antigen doubling times in patients who have failed radical prostatectomy: correlation with histologic characteristics of the primary cancer. Urology. 1997;49:737-742 (Pubitemid 27194590)
19. Goluboff ET, Heitjan DF, DeVries GM, et al. Pretreatment prostate specific antigen doubling times: use in patients before radical prostatectomy. J Urol. 1997;158:1876-1879
20. Humphrey PA, Vollmer RT. Relationships between serum prostate specific antigen and histopathologic appearances of prostate carcinoma. In: Foster CS, Bostwick DG, eds. Pathology of the Prostate. Philadelphia, PA: Saunders; 1998:269-281
21. Nam RK, Klotz LM, Jewett MAS, et al. Prostate specific antigen velocity as a measure of the natural history of prostate cancer: defining a "rapid riser" subset. Br J Urol. 1998;81:100-104
22. Vollmer RT, Dawson NA, Vogelzang NJ. The dynamics of prostate specific antigen in hormone refractory prostate carcinoma: an analysis of Cancer and Leukemia Group B study 9181 of megestrol acetate. Cancer. 1998;83:1989-1994
23. Vollmer RT, Montana GS. The dynamics of prostate-specific antigen after definitive radiation therapy for prostate cancer. Clin Cancer Res. 1999;5:4119-4125 (Pubitemid 30013794)
24. Epstein JI, Walsh PC, Akingba G, et al. The significance of prior benign needle biopsies in men subsequently diagnosed with prostate cancer. J Urol. 1999;162:1649-1652 (Pubitemid 29474683)
25. Vollmer RT, Kantoff PW, Dawson NA, et al. A prognostic score for hormone-refractory prostate cancer: analysis of two Cancer and Leukemia Group B studies. Clin Cancer Res. 1999;5:831-837
26. Freedland SJ, Dorey F, Aronson WJ. Preoperative PSA velocity and doubling time do not predict adverse pathological features or biochemical recurrence after prostatectomy. Urology. 2001;57:476-480 (Pubitemid 32201136)
27. Vollmer RT, Egawa S, Kuwao S, et al. The dynamics of prostate specific antigen during watchful waiting of prostate carcinoma: a study of 94 Japanese men. Cancer. 2002;94:1692-1698 (Pubitemid 34241106)
28. Fang J, Metter EJ, Landis P, et al. PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/mL. Urology. 2002;59:889-894 (Pubitemid 34522182)
29. D'Amico AV, Chen M-H, Roehl KA, et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004;351:125-135
30. Roobol MJ, Kranse R, De Koning HJ, et al. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (Rotterdam). Urology. 2004;63:309-315 (Pubitemid 38234425)
31. Choo R, Klotz L, Deboer G, et al. Wide variation of prostate-specific antigen doubling time of untreated, clinically localized, low-to-intermediate grade, prostate cancer. BJU Int. 2004;94:295-298 (Pubitemid 39120166)
32. D'Amico AV, Moul J, Carroll PR, et al. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol. 2004;172(5 pt 2):S42-S47 (Pubitemid 39350557)
33. Raaijmakers R, Wildhagen MF, Ito K, et al. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. Urology. 2004;63:316-320 (Pubitemid 38234427)
34. D'Amico AV, Renshaw AA, Sussman B, et al. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA. 2005;294:440-447 (Pubitemid 41124176)
35. Patel DA, Presti JC Jr, McNeal JE, et al. Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy. J Clin Oncol. 2005;23:6157-6162 (Pubitemid 46300234)
36. Sengupta S, Myers RP, Slezak JM, et al. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol. 2005;174:2191-2196 (Pubitemid 41611772)
37. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294:433-439 (Pubitemid 41124175)
38. Schröder FH, Roobol MJ, van der Kwast TH, et al. Does PSA velocity predict prostate cancer in pre-screened populations? Eur Urol. 2006;49:460-465 (Pubitemid 43259552)
39. Eggener SE, Roehl KA, Yossepowitch O, et al. Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy. J Urol. 2006;176:1399-1403 (Pubitemid 44307226)
40. Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006;98:529-534 (Pubitemid 43898816)
41. Benecchi L. PSA velocity and PSA slope. Prostate Cancer Prostatic Dis. 2006;9:169-172
42. Zhang L, Loblaw A, Klotz L. Modeling prostate specific antigen kinetics in patients on active surveillance. J Urol. 2006;176:1392-1398 (Pubitemid 44316856)
43. Yu X, Loeb S, Roehl KA, et al. The association between total prostate specific antigen concentration and prostate specific antigen velocity. J Urol. 2007;177:1298-1302 (Pubitemid 46436021)
44. King CR, Freedland SJ, Terris MK, et al. Optimal timing, cutoff, and method of calculation of preoperative prostate specific antigen velocity to predict relapse after prostatectomy: a report from SEARCH. Urology. 2007;69:732-737
45. Perlmuter MA, Lepor H. Prostate-specific antigen doubling time is a reliable predictor of imageable metastases in men with biochemical recurrence after radical retropubic prostatectomy. Urology. 2008;71:501-505 (Pubitemid 351374706)
46. Benecchi L, Pieri AM, Pastizzaro CD, et al. Optimal measure of PSA kinetics to identify prostate cancer. Urology. 2008;71:390-394 (Pubitemid 351374708)
47. Eggener SE, Yossepowitch O, Roehl KA, et al. Relationship of prostate specific antigen velocity to histologic findings in a prostate cancer screening program. Urology. 2008;71:1016-1019
48. Hamilton RJ, Aronson WJ, Terris MK, et al. Limitations of prostate specific antigen doubling time following biochemical recurrence after radical prostatectomy: results from the SEARCH database. J Urol. 2008;179:1785-1790
49. Ulmert DCA, O'Brien MF, Becker C, et al. Long-term prediction of prostate cancer: PSA velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. J Clin Oncol. 2008;26:835-841 (Pubitemid 351398073)
50. Vollmer RT, Humphrey PA. Tumor volume in prostate cancer and serum prostate-specific antigen: analysis from a kinetic viewpoint. Am J Clin Pathol. 2003;119:80-89
51. Vollmer RT. Percentage of tumor in prostatectomy specimens: a study of American Veterans. Am J Clin Pathol. 2009;131:86-91